Ocugen, Inc.
OCU410
Geographic Atrophy
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for OCU410 in Geographic Atrophy are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“Upcoming Global Phase 3 , n=~300, adaptive design, >95% power, 3Q 2026 (Target)”